Neuraxpharm

Neuraxpharm is a well-established, privately-held European pharmaceutical company specializing in CNS disorders, operating in a high-need therapeutic area affecting one in three people globally. The company has evolved from a generic drug focus to a diversified CNS specialist with a portfolio spanning generics, branded established products, digital health devices, and partnerships for innovative therapies. Its strategy is built on geographic expansion across Europe, strategic acquisitions, and forging alliances to enhance its product offerings and address gaps in CNS care, positioning it for continued growth in a complex but critical market.

CNS-focused specialization in formulation, lifecycle management, and integrated digital health solutions (e.g., wearable devices). Core initiative: 'Naxiva' for innovative CNS treatments.

Neuraxpharm competes with large generic pharmaceutical companies, global CNS-focused pharma giants, and specialized biotechs. Its differentiation lies in its pure CNS focus, pan-European commercial footprint, and hybrid portfolio spanning generics, established brands, and digital health.